American Association for Cancer Research
21598290cd130900-sup-123011_3_supp_2592134_n9mvw7.pdf (5.66 MB)

Supplemental Figures S1-S5, Table S1 from Development of siRNA Payloads to Target KRAS-Mutant Cancer

Download (5.66 MB)
journal contribution
posted on 2023-04-03, 20:48 authored by Tina L. Yuan, Christof Fellmann, Chih-Shia Lee, Cayde D. Ritchie, Vishal Thapar, Liam C. Lee, Dennis J. Hsu, Danielle Grace, Joseph O. Carver, Johannes Zuber, Ji Luo, Frank McCormick, Scott W. Lowe

Supplemental Figure S1. Sensor-based generation of a functionally validated sh/siRNA library targeting Ras pathway genes. Figure S2. Validation of Sensor siRNAs targeting components in the MAPK pathway. Figure S3. Dose dependent off-target effects of sh/siRNAs. Figure S4. Sensor siRNA pooling effects. Figure S5. In vivo fluorescence reporter system. Table S1. Correlation of library reads and Sensor score.



RNAi is a powerful tool for target identification and can lead to novel therapies for pharmacologically intractable targets such as KRAS. RNAi therapy must combine potent siRNA payloads with reliable in vivo delivery for efficient target inhibition. We used a functional “Sensor” assay to establish a library of potent siRNAs against RAS pathway genes and to show that they efficiently suppress their targets at low dose. This reduces off-target effects and enables combination gene knockdown. We administered Sensor siRNAs in vitro and in vivo and validated the delivery of KRAS siRNA alone and siRNA targeting the complete RAF effector node (A/B/CRAF) as promising strategies to treat KRAS-mutant colorectal cancer. We further demonstrate that improved therapeutic efficacy is achieved by formulating siRNA payloads that combine both single-gene siRNA and node-targeted siRNAs (KRAS + PIK3CA/B). The customizable nature of Sensor siRNA payloads offers a universal platform for the combination target identification and development of RNAi therapeutics.Significance: To advance RNAi therapy for KRAS-mutant cancer, we developed a validated siRNA library against RAS pathway genes that enables combination gene silencing. Using an in vivo model for real-time siRNA delivery tracking, we show that siRNA-mediated inhibition of KRAS as well as RAF or PI3K combinations can impair KRAS-mutant colorectal cancer in xenograft models. Cancer Discov; 4(10); 1182–97. ©2014 AACR.This article is highlighted in the In This Issue feature, p. 1103